GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Whitehawk Therapeutics Inc (NAS:WHWK) » Definitions » Book Value per Share

WHWK (Whitehawk Therapeutics) Book Value per Share : $2.13 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Whitehawk Therapeutics Book Value per Share?

Whitehawk Therapeutics's book value per share for the quarter that ended in Dec. 2024 was $2.13.

During the past 12 months, Whitehawk Therapeutics's average Book Value Per Share Growth Rate was -50.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -31.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Whitehawk Therapeutics was -31.20% per year. The lowest was -31.20% per year. And the median was -31.20% per year.

Whitehawk Therapeutics's current price is $1.725. Its book value per share for the quarter that ended in Dec. 2024 was $2.13. Hence, today's PB Ratio of Whitehawk Therapeutics is 0.81.

During the past 5 years, the highest P/B Ratio of Whitehawk Therapeutics was 4.01. The lowest was 0.38. And the median was 1.25.


Whitehawk Therapeutics Book Value per Share Historical Data

The historical data trend for Whitehawk Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Whitehawk Therapeutics Book Value per Share Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
-0.60 6.53 6.48 4.28 2.13

Whitehawk Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 3.68 3.20 2.80 2.13

Competitive Comparison of Whitehawk Therapeutics's Book Value per Share

For the Biotechnology subindustry, Whitehawk Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Whitehawk Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Whitehawk Therapeutics's PB Ratio falls into.


;
;

Whitehawk Therapeutics Book Value per Share Calculation

Whitehawk Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(52.48-0.00)/24.68
=2.13

Whitehawk Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(52.48-0.00)/24.68
=2.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Whitehawk Therapeutics  (NAS:WHWK) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Whitehawk Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Whitehawk Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Whitehawk Therapeutics Business Description

Traded in Other Exchanges
Address
2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Executives
David James Lennon director, officer: Chief Executive Officer C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Neil Desai director, officer: See Remarks C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Lorettta M Itri officer: Chief Medical Officer
Brendan Delaney officer: Chief Operating Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun director C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault officer: Chief Financial Officer
Behzad Aghazadeh director, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc director, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc director, other: See Remarks 110 GREEN STREET, SUITE 800, NEW YORK NY 10012